利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

27 条记录 (耗时 0.052 秒)

    Process for the preparation of Tazobactam in pure form
    1.
    发明授权
    Process for the preparation of Tazobactam in pure form 失效
    以纯形式制备他唑巴坦的方法

    公开(公告)号：US07417143B2

    公开(公告)日：2008-08-26

    申请号：US11098526

    申请日：2005-04-05

    申请人： Andrew Gnanaprakasam ,  Udayampalayam Palanisamy Senthilkumar ,  Gaddam Om Reddy

    发明人： Andrew Gnanaprakasam ,  Udayampalayam Palanisamy Senthilkumar ,  Gaddam Om Reddy

    IPC分类号： C07D499/18

    CPC分类号： C07D499/00

    摘要： An improved process for the purification of tazobactam or its derivatives of the formula (I) wherein R represents hydrogen, C1-C6alkyl, p-methoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, o-chlorobenzyl, benzyl or diphenylmethyl, which comprises the steps of: i) slurrying the compound of formula (I) containing the impurity of the formula (V) using a solvent in the presence or absence of tartaric acid with or without the presence of water at 20-50° C. and ii) isolating the compound of formula (I) in pure form.

    摘要翻译： 用于纯化式（I）的他唑巴坦或其衍生物的改进方法，其中R表示氢，C 1 -C 6烷基，对甲氧基苄基，邻 - 硝基苄基 ，对硝基苄基，邻氯苄基，苄基或二苯基甲基，其包括以下步骤：i）在存在或不存在酒石酸的情况下，使用溶剂将含有式（V）的杂质的式（I）化合物在酒石酸存在或不存在下， 或在20-50℃下不存在水，和ii）以纯形式分离式（I）化合物。

    Pyrimidine carboxamides
    3.
    发明授权
    Pyrimidine carboxamides 失效
    嘧啶甲酰胺

    公开(公告)号：US07759350B2

    公开(公告)日：2010-07-20

    申请号：US11516549

    申请日：2006-09-07

    申请人： Ravikumar Tadipartiii ,  Venkatesan Parameswaran ,  Rajib Barik ,  Gaddam Om Reddy ,  Pawan Aggarwal ,  Sappanimuthu Thirunavukkarasu ,  Sriram Rajagopal

    发明人： Ravikumar Tadipartiii ,  Venkatesan Parameswaran ,  Rajib Barik ,  Gaddam Om Reddy ,  Pawan Aggarwal ,  Sappanimuthu Thirunavukkarasu ,  Sriram Rajagopal

    IPC分类号： C07D239/28 ,  A61K31/505

    CPC分类号： C07D239/38 ,  C07D239/46 ,  C07D239/47 ,  C07D239/48 ,  C07D401/04

    摘要： The present invention relates to novel compounds of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and compositions, their metabolites and prodrugs thereof. The present invention more particularly relates to novel pyrimidine carboxamides of the general formula (I). Also included is a method of prophylaxis or treatment of a pain disorder, immunological diseases, inflammation, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; ischemic heart disease; atherosclerosis; cancer; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; cachexia; asthma; bone resorption diseases; ischemia reperfusion injury; brain trauma; multiple sclerosis; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection in a mammal comprising administering an effective amount of a compound of formula (I) as described above.

    摘要翻译： 本发明涉及通式（I）的新化合物，其衍生物，其类似物，其互变异构形式，其立体异构体，其多晶型物，它们的水合物，它们的溶剂化物，其药学上可接受的盐和组合物，其代谢物和前药。 本发明更具体地涉及通式（I）的新型嘧啶甲酰胺。 还包括预防或治疗疼痛障碍，免疫疾病，炎症，类风湿性关节炎的方法; 骨质疏松症 多发性骨髓瘤 葡萄膜炎 急性和慢性粒细胞白血病; 缺血性心脏病; 动脉粥样硬化 癌症; 缺血诱导的细胞损伤; 胰腺β细胞破坏; 骨关节炎 类风湿性脊柱炎; 痛风性关节炎 炎症性肠病; 成人呼吸窘迫综合征（ARDS）; 银屑病; 克罗恩病; 过敏性鼻炎; 溃疡性结肠炎 过敏反应 接触性皮炎; 肌肉退化; 恶病质 哮喘; 骨吸收疾病; 缺血再灌注损伤; 脑外伤; 多发性硬化症 败血症 败血性休克 中毒性休克综合征; 发热和由于哺乳动物感染引起的肌痛，包括给予有效量的如上所述的式（I）化合物。